Latest Financial Performance News

Frontier Energy Limited reported a sharp 90% increase in net loss to $210,593 for the half year ended June 2025, with no revenue recorded and no dividends declared.

AUCyber Limited reported a 112% revenue increase to $23 million in FY25, driven by acquisitions and cybersecurity growth, despite a $37.6 million net loss largely due to impairment charges. The company’s strategic pivot under 5G Networks’ majority ownership signals a renewed focus on sovereign cloud and AI-enhanced security services.

Thorney Technologies Ltd reported a reduced net loss of $4.66 million for FY2025, improving from a $21.7 million loss the previous year, while maintaining a stable net tangible asset backing per share. The company is focused on enhancing portfolio performance and addressing the persistent discount to net tangible assets through strategic initiatives including a share buyback.

The company posted a 25% increase in net loss to $709,247 for the year ended June 2025, alongside a sharp 55% drop in revenue. Key factors include significant trading losses and lower interest income, with no dividends declared.

Audeara Limited reported a 19% revenue increase to $3.79 million for FY25, driven by strong Australian wholesale growth and expanding international partnerships. Despite a net loss of $1.79 million, the company’s AUA Technology division and new licensing deals position it for future profitability.

DataDot Technology Limited reported a 13% revenue increase and a 56% rise in net profit after tax for FY25, driven by growth in its PropertyVAULT insurance services and new distributor partnerships.

Kinatico Limited has reported a robust 12% increase in revenue and a striking 45% rise in profit after tax for the financial year ended June 2025, underscoring solid operational momentum despite no dividend payouts.

Cleo Diagnostics reported a $4 million loss for FY2025 while making significant strides toward FDA approval of its novel ovarian cancer blood test. The company is progressing clinical trials and scaling manufacturing in preparation for market entry.

Race Oncology Limited reported a significantly reduced loss for FY2025, driven by key clinical trial progress and strategic leadership changes. The company advances its RC220 program with promising Phase 1 dosing milestones and strengthens its governance to support future growth.

Ironbark Capital Limited reported a 17.6% increase in net profit for FY2025, driven by higher investment income and realised gains, alongside a raised fully franked dividend and an extended share buy-back program.

Eildon Capital Group reported a $5.7 million net loss in FY25, weighed down by $8 million in one-off charges, while simplifying its portfolio and entering a new joint venture in North Queensland.

Eildon Capital Group reported a net loss of $5.7 million for FY2025, weighed down by significant one-off impairments, while pivoting to focused real estate investments with a new $20.8 million joint venture in Queensland.